Jiangsu Yuyue Medical Equipment & Supply Co Ltd

Jiangsu Yuyue Medical Equipment & Supply Co Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.0 and a current ratio of 1.54. The balance sheet reflects total assets of 16.08 billion CNY against total liabilities of 2.84 billion CNY, resulting in total equity of 13.24 billion CNY. Long-term debt is minimal at 46.93 million CNY. Despite the low leverage, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting potential short-term cash management pressures despite strong operating cash flow of 1.50 billion CNY.

Profitability metrics indicate a gross profit of 4.00 billion CNY on revenue of 7.96 billion CNY, yielding a gross margin of approximately 50.3%. Operating income stands at 1.70 billion CNY, and net income is 1.48 billion CNY. The company generates a return on equity (ROE) of 9.71% and a return on assets (ROA) of 7.99%. These returns are supported by a free cash flow of 814.76 million CNY, derived from operating cash flow of 1.50 billion CNY less capital expenditures of 128.98 million CNY.

Segment and geographic revenue mix data is not provided in the available input, preventing a detailed analysis of revenue concentration or regional exposure. The company’s business activity is broadly categorized under Health Care Equipment & Supplies, but specific product lines or customer concentrations are not disclosed in the current dataset.

Growth trajectory analysis is limited by the absence of historical period data in the input. The current financial snapshot provides a single-period view of revenue at 7.96 billion CNY and net income at 1.48 billion CNY, but year-over-year trends or multi-year growth rates cannot be calculated from the provided information.

Risk factors include medium liquidity risk and low dilution risk. A key flag indicates that net cash is negative after subtracting total debt, which may impact short-term financial flexibility. The dilution risk is assessed as low, with basic and diluted shares outstanding both at 1.00 billion, indicating no significant dilutive securities currently impacting the share count.

Recent events and market sentiment are reflected in analyst estimates, with a mean price target of 42.44 CNY and a median target of 44.53 CNY, suggesting upside potential from the current market price of 26.45 CNY. The mean recommendation is 1.43, indicating a strong buy consensus, with 4 strong buy ratings and 3 buy ratings, and no hold ratings. No specific filing, news, or transcript observations are provided in the input.

Analysts project 53.1% upside to a mean price target of 42.44, reflecting strong buy consensus among seven analysts.

The company maintains a zero debt-to-equity ratio, providing a pristine balance sheet compared to the cohort median of 0.4.

Free cash flow is projected to grow 16.9% year-over-year to 814.8 million CNY in fiscal 2026.

Return on invested capital stands at 11.0%, indicating efficient capital deployment relative to the company's asset base.

Operating income is expected to drop 12.0% year-over-year to 1.70 billion CNY in fiscal 2026.

Revenue growth has slowed to a 3.6% four-year CAGR, indicating limited top-line expansion momentum.

The company faces medium liquidity risk, which could constrain operational flexibility or dividend sustainability.

Cash conversion ratio of 1.17 trails the cohort median of 1.2, suggesting slightly less efficient cash generation.

Revenue ¥2.37B, −2,7% YoY; Operating income −32,0% YoY.

• ▍Revenue ¥2.37B, −2,7% YoY
• ▍Operating income −32,0% YoY
• ▍Net income −31,4% YoY
• ▍Net margin 18.1%

Revenue ¥1.41B, −8,3% YoY; Operating income −91,4% YoY.

• ▍Revenue ¥1.41B, −8,3% YoY
• ▍Operating income −91,4% YoY
• ▍Net income −94,2% YoY
• ▍Net margin 1.1%

Revenue ¥1.89B, +9,6% YoY; Operating income −35,9% YoY.

• ▍Revenue ¥1.89B, +9,6% YoY
• ▍Operating income −35,9% YoY
• ▍Net income −36,0% YoY
• ▍Net margin 14.0%

Revenue ¥2.22B, +7,1% YoY; Operating income +27,2% YoY.

• ▍Revenue ¥2.22B, +7,1% YoY
• ▍Operating income +27,2% YoY
• ▍Net income +25,4% YoY
• ▍Net margin 26.0%

Revenue ¥2.44B; Operating income ¥736.9M.

• ▍Revenue ¥2.44B
• ▍Operating income ¥736.9M
• ▍Net margin 25.6%

Revenue ¥7.96B, +5,1% YoY; Operating income −12,0% YoY.

• ▍Revenue ¥7.96B, +5,1% YoY
• ▍Operating income −12,0% YoY
• ▍Net income −17,9% YoY
• ▍Free cash flow +16,9% YoY
• ▍Net margin 18.6%

Revenue ¥7.57B, −5,1% YoY; Operating income −33,2% YoY.

• ▍Revenue ¥7.57B, −5,1% YoY
• ▍Operating income −33,2% YoY
• ▍Net income −24,6% YoY
• ▍Free cash flow −61,6% YoY
• ▍Net margin 23.9%

Revenue ¥7.97B, +12,2% YoY; Operating income +57,1% YoY.

• ▍Revenue ¥7.97B, +12,2% YoY
• ▍Operating income +57,1% YoY
• ▍Net income +50,2% YoY
• ▍Free cash flow +71,4% YoY
• ▍Net margin 30.1%

Revenue ¥7.10B, +3,0% YoY; Operating income +9,1% YoY.

• ▍Revenue ¥7.10B, +3,0% YoY
• ▍Operating income +9,1% YoY
• ▍Net income +7,6% YoY
• ▍Free cash flow −2,0% YoY
• ▍Net margin 22.5%

Revenue ¥6.89B; Operating income ¥1.69B.

• ▍Revenue ¥6.89B
• ▍Operating income ¥1.69B
• ▍Net margin 21.5%